AMG 162 — Competitive Intelligence Brief

AMG 162 (AMG 162) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RANKL inhibitor monoclonal antibody. Area: Bone metabolism / Oncology.

phase 3 RANKL inhibitor monoclonal antibody RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) Bone metabolism / Oncology Small molecule

Target snapshot

AMG 162 (AMG 162) — Amgen. AMG 162 is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AMG 162 TARGET	AMG 162	Amgen	phase 3	RANKL inhibitor monoclonal antibody	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab De-escalation	Denosumab De-escalation	National Taiwan University Hospital	marketed	RANKL inhibitor monoclonal antibody de-escalation strategy	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
ABP 654	ABP 654	Amgen	phase 3	RANKL inhibitor monoclonal antibody	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RANKL inhibitor monoclonal antibody class)

1. Amgen · 2 drugs in this class